Page last updated: 2024-12-06

elgodipine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

elgodipine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID60701
CHEMBL ID2218890
SCHEMBL ID49350
MeSH IDM0176066

Synonyms (19)

Synonym
elgodipine
3-o-[2-[(4-fluorophenyl)methyl-methylamino]ethyl] 5-o-propan-2-yl 4-(1,3-benzodioxol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
119413-55-7
3,5-pyridinedicarboxylic acid, 4-(1,3-benzodioxol-4-yl)-1,4-dihydro-2,6-dimethyl-, 2-(((4-fluorophenyl)methyl)methylamino)ethyl 1-methylethyl ester, (+-)-
elgodipino
unii-3ji11z5ref
2-((p-fluorobenzyl)methylamino)ethyl isopropyl (+-)-1,4-dihydro-2,6-dimethyl-4-(2,3-(methylenedioxy)phenyl)-3,5-pyridinedicarboxylate
elgodipine [inn]
elgodipino [inn-spanish]
3ji11z5ref ,
elgodipinum
elgodipinum [inn-latin]
CHEMBL2218890
2-((p-fluorobenzyl)methylamino)ethyl isopropyl (+/-)-1,4-dihydro-2,6-dimethyl-4-(2,3-(methylenedioxy)phenyl)-3,5-pyridinedicarboxylate
elgodipine [mi]
SCHEMBL49350
2-{[(4-fluorophenyl)methyl](methyl)amino}ethyl propan-2-yl 4-(2h-1,3-benzodioxol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
DTXSID20922957
Q27257299

Research Excerpts

Overview

Elgodipine is a potent systemic and coronary vasodilator with more marked direct cardiac effects than nicardipine. It is a new second-generation dihydropyridine calcium antagonist.

ExcerptReferenceRelevance
"4. Elgodipine is a potent systemic and coronary vasodilator with more marked direct cardiac effects than nicardipine, particularly with respect to slowing of heart rate."( Comparison of the haemodynamic profiles of elgodipine and nicardipine in the anaesthetized dog.
Drieu la Rochelle, CD; Grosset, A; O'Connor, SE, 1994
)
1.07
"Elgodipine is a new second-generation dihydropyridine calcium antagonist. "( Hemodynamic and antiischemic effects of intravenous elgodipine, a new dihydropyridine calcium channel blocker, in patients with chronic stable angina.
Carlsson, J; Kuhn, A; Miketic, S; Tebbe, U, 1995
)
1.98

Pharmacokinetics

ExcerptReferenceRelevance
" In the elgodipine plasma concentration profile (HPLC), three phases of elimination with half-life times of less than 1 hour, between 3 and 7 hours, and between 10 and 24 hours may be distinguished, indicating a "shallow" and a "deep" compartment."( Hemodynamic effects of intravenous elgodipine in coronary artery disease during rest and exercise, and basic pharmacokinetic parameters.
de la Motte, S; Drake, M; Harrison, FJ; Herity, NA; Kelly, J; Silke, B; Spiers, P, 1996
)
1.01
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's16 (94.12)18.2507
2000's1 (5.88)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (23.53%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (76.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]